SBCSBC Medical Group Holdings Incorporated

$5.33+29% 1Y

Is the price fair?

Good

Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 good, 2 without data
What the price assumes~−5% a yearderived · Jun 30, 2026

Priced for a decline (~−5% a year). The price bakes in little to no growth.

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What SBC's price assumes

SBC Medical Group Holdings Incorporated trades at 11.3× earnings against 18.0× for the median Consulting Services name, cheaper than its own group.

11.3

Trailing P/E · Consulting Services median 18.0 · cheaper than the typical name in its group

Price / sales
2.54

Price / sales · as of 2026-Q1

Free cash flow yield
11%

Free cash flow yield · Consulting Services median 8.5%

Growth the price implies
−5.3%

Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.

Details›
Price / bookas of 2026-Q1
1.68
EV / EBITas of 2026-Q1
5.16
EV / salesas of 2026-Q1
1.86
Industrials median P/E440 names
26.5
Consulting Services median P/E10 names
18.0
Free cash flow, trailing twelve months
$62M
Market capitalisation
$548M

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.